Lombardi G - Search Results

1

Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma.

Visca P, Sebastiani V, Botti C, Diodoro MG, Lasagni RP, Romagnoli F, Brenna A, De Joannon BC, Donnorso RP, Lombardi G, Alo PL. Visca P, et al. Among authors: lombardi g. Anticancer Res. 2004 Nov-Dec;24(6):4169-73. Anticancer Res. 2004. PMID: 15736468 Free article.

2

Fatty acid synthase expression in Paget's disease of the vulva.

Alo PL, Galati GM, Sebastiani V, Ricci F, Visca P, Mariani L, Romagnoli F, Lombardi G, Tondo UD. Alo PL, et al. Among authors: lombardi g. Int J Gynecol Pathol. 2005 Oct;24(4):404-8. doi: 10.1097/01.pgp.0000170065.53813.81. Int J Gynecol Pathol. 2005. PMID: 16175090

3

Vulvar cancer: prognostic factors.

Nicoletto MO, Parenti A, Del Bianco P, Lombardi G, Pedrini L, Pizzi S, Carli P, Della Palma M, Pastorelli D, Corti L, Becagli L. Nicoletto MO, et al. Among authors: lombardi g. Anticancer Res. 2010 Jun;30(6):2311-7. Anticancer Res. 2010. PMID: 20651385

4

Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.

Losa M, Bogazzi F, Cannavo S, Ceccato F, Curtò L, De Marinis L, Iacovazzo D, Lombardi G, Mantovani G, Mazza E, Minniti G, Nizzoli M, Reni M, Scaroni C. Losa M, et al. Among authors: lombardi g. J Neurooncol. 2016 Feb;126(3):519-25. doi: 10.1007/s11060-015-1991-y. Epub 2015 Nov 27. J Neurooncol. 2016. PMID: 26614517

5

Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Versus Delayed Administration.

Pasqualetti F, Gonnelli A, Molinari A, Cantarella M, Montrone S, Cristaudo A, Baldaccini D, Mattioni R, Delishaj D, Mazzotti V, Morganti R, Cocuzza P, Fabrini MG, Lombardi G, Rudà R, Soffietti R, Paiar F. Pasqualetti F, et al. Among authors: lombardi g. Anticancer Res. 2018 Oct;38(10):5877-5881. doi: 10.21873/anticanres.12930. Anticancer Res. 2018. PMID: 30275213

6

A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.

Zustovich F, Lombardi G, Della Puppa A, Rotilio A, Scienza R, Pastorelli D. Zustovich F, et al. Among authors: lombardi g. Anticancer Res. 2009 Oct;29(10):4275-9. Anticancer Res. 2009. PMID: 19846986 Free article. Clinical Trial.

7

Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.

Zustovich F, Lombardi G, Pastorelli D, Farina P, Furini L, Manara R, Dalla Palma M, Rotilio A, Nicoletto O, Zagonel V. Zustovich F, et al. Among authors: lombardi g. Anticancer Res. 2010 Dec;30(12):5213-6. Anticancer Res. 2010. PMID: 21187515

8

Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.

Zustovich F, Landi L, Lombardi G, Porta C, Galli L, Fontana A, Amoroso D, Galli C, Andreuccetti M, Falcone A, Zagonel V. Zustovich F, et al. Among authors: lombardi g. Anticancer Res. 2013 Aug;33(8):3487-94. Anticancer Res. 2013. PMID: 23898124 Clinical Trial.

9

Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series.

Zustovich F, Ferro A, Lombardi G, Zagonel V, Fiduccia P, Farina P. Zustovich F, et al. Among authors: lombardi g. Anticancer Res. 2013 Sep;33(9):4061-5. Anticancer Res. 2013. PMID: 24023350

10

Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.

Lombardi G, Di Stefano AL, Farina P, Zagonel V, Tabouret E. Lombardi G, et al. Cancer Treat Rev. 2014 Sep;40(8):951-9. doi: 10.1016/j.ctrv.2014.05.007. Epub 2014 May 27. Cancer Treat Rev. 2014. PMID: 24909312 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,061 results

Search Page